Grants>Infectious Diseases

Call for Nominations: Gates Vaccine Innovation Award

Hundreds of thousands of lives each year could be saved by improved access to vaccines. Vaccines are cost-effective, safe, and proven to protect children from disease.

Continued innovation is essential to overcoming persistent challenges in reaching more children with vaccines.

The Gates Vaccine Innovation Award will celebrate revolutionary ways children in the poorest parts of the world are immunized. The winning innovation will be recognized with a US $250,000 prize.

The Gates Vaccine Innovation Award is open to individuals from any discipline. Candidates from academic institutions, governments, health care facilities, research institutions, non-profit organizations and for-profit companies may be nominated.

Criteria

We recognize that innovation in the delivery of vaccines can take many shapes. We are looking for ideas big or small that have resulted in tangible improvements in immunization coverage in developing country communities. 

Nominees will be assessed on three broad criteria:

Developing country impact – The nominee should have contributed to the prevention, control, or elimination of vaccine-preventable disease through significant improvements in immunization quality and coverage among mothers and children in developing countries.

Innovation and creativity – The nominee should have applied imaginative and pioneering approaches to overcome difficult challenges to immunizing children and achieving impact. Innovation is not the same as invention. Even simple ideas applied in creative ways to overcome real-world challenges can be considered innovative.

Scale – The nominee’s innovation should be at scale or suitable to be implemented at scale within the nominee’s country and around the world.

If you are unable to complete the online nomination form, please send an email to vaccine-innovation-award@gatesfoundation.org to request a Word version of the nomination form. Please submit these nominations via email to vaccine-innovation-award@gatesfoundation.org, or via fax to +1-206-494-7042.

Nominations will be accepted through 11:59 PM Pacific Standard Time on July 31, 2013.

Qualifications

In order to qualify for consideration:

Nominations must be related to vaccine delivery and meet the criteria above

Nomination forms must be completed in English

The three essay questions should be answered within the font and word-limit requirements

Please note that nominations focused on innovation in research & development are not eligible for consideration. This award is focused only on achieving impact through innovative systems, processes, tools, and technologies leading to better immunization.

Request for Proposals: 2013 ASPIRE Awards in Adult Vaccine Research

Mission

The mission of the 2013 ASPIRE Awards in Adult Vaccine Research is to advance medical knowledge to better understand the burden of pneumococcal disease in adults.

The burden of pneumococcal disease in the general adult population has been extensively studied; however, it is not well-defined in special populations, including subgroups with underlying disease comorbidities and/or those living in long-term community settings.

Pfizer invites investigators to apply for the 2013 ASPIRE Awards in Adult Vaccine Research through submission of innovative research proposals for evaluation of the epidemiology and burden of pneumococcal disease in adults with underlying disease comorbidities and/or those living in long-term community settings.

2013 Research Topic

Evaluating the Burden of Pneumococcal Disease in Adults in the United States

An applicant should have a strong research interest within the areas of focus and should consider the following components when developing their research proposals:

A. The burden of pneumococcal disease and serotype distribution in adults including but not limited to:

• Individuals with increased risk of pneumococcal disease including those with underlying comorbidities.

Comorbidities may include but are not limited to:

◦ Diabetes mellitus

◦ Chronic obstructive pulmonary disease (COPD) or other chronic pulmonary disorder

◦ Oncologic disorders

◦ Chronic renal disease

◦ Hepatic disease

◦ Autoimmune disorders

• Those living in community settings (e.g., extended-care facilities, correctional institutions).

• Regional evaluation of pneumococcal resistance and serotype distribution.

• Carriage of Streptococcus pneumoniae in the adult population.

B. Association of pneumococcal pneumonia with influenza or other respiratory viral illnesses

C. The following topics fall outside of the scope of the ASPIRE Adult Vaccine Research Program:

• General education and / or training.

• Support for ongoing clinical programs that are part of an organization’s routine operations.

• Proposals that evaluate populations outside of the United States or Puerto Rico.

Proposals whose primary objective is to financially quantify outcomes as it relates to a Pfizer product(s) are outside the scope of the program.

Research Expectations

Within the specified patient populations of interest, investigators are expected to:

• Generate data regarding the burden of pneumococcal disease in adults and/or evaluation of adult vaccination efforts.

• Be able to complete the research in 12 months.

• Present and/or publish the results of the study.

Available Awards

Pfizer is funding research awards up to a maximum of $100,000 USD* each (including direct costs, institutional overhead costs, and indirect costs) for one year to conduct research generating data that will lead to a better understanding of burden of pneumococcal disease in adults.

*Please note that study budgets will be evaluated separately to ensure the requested funding is commensurate with the work proposed.

Deadline for Application

Applications must be received by 11:59pm EST on July 2, 2013. 

Request for Proposals: Society of Infectious Diseases Pharmacists Infectious Diseases Pharmacotherapy Young Investigator Research Award

SIDP is soliciting ID pharmacotherapy research proposals from SIDP members who qualify as young investigators. 

The primary purpose of the research award is to provide funding for research projects that will contribute to the further development of the principal investigator’s research career and improve their competitiveness for future extramural funding.  Favorable consideration will be given to research proposals which focus on current pharmacotherapy issues surrounding the prevention and management of infectious diseases.  Applications must be submitted no later than 5PM E.S.T on Friday, August 9, 2013.

Funding:  Financial support for individual proposals is limited to $10,000.

Merck Irving S. Sigal Memorial Awards

Recognize and award excellence in basic research in medical microbiology and infectious diseases. The awards are presented in memory of Irving S. Sigal, who was instrumental in the early discovery of therapies to treat HIV/AIDS.

Eligibility:
The nominee must be no more than five years beyond completion of postdoctoral research training in microbiology or infectious diseases at the time of the nomination deadline.

Award:
A cash prize of $2,500 and a commemorative piece. Up to two awards may be given each year at the ASM General Meeting where they are presented.

Deadline: July 1.

Nominations:
Nominations will be reconsidered annually so long as eligibility criteria are met and an updated curriculum vitae is submitted. Self-nominations and more than one nomination per nominee will not be accepted. Only one nominating form and two supporting forms are accepted per nomination. The two supporters must be persons other than the nominator who are familiar with the nominee's qualifications and accomplishments. Only one of the three individuals involved in the nomination may be employed at the nominee's institution. The nominator and supporters must not share employers. Nominations must consist of the following:
 

Curriculum vitae, including a list of publications, emailed to awards@asmusa.org
Nominating form
Supporting form

ASM awards are granted at the discretion of award selection committees and may not be awarded every year.

Sponsor: Merck Research Laboratories